Analysts See $0.55 EPS for Ormat Technologies, Inc. (ORA); Perceptive Advisors Boosted Its Neurocrine Biosciences (NBIX) Position

February 19, 2018 - By Linda Rogers

Perceptive Advisors Llc increased Neurocrine Biosciences Inc (NBIX) stake by 33.93% reported in 2017Q3 SEC filing. Perceptive Advisors Llc acquired 1.21 million shares as Neurocrine Biosciences Inc (NBIX)’s stock rose 19.84%. The Perceptive Advisors Llc holds 4.79 million shares with $293.63 million value, up from 3.58M last quarter. Neurocrine Biosciences Inc now has $7.61B valuation. The stock decreased 0.37% or $0.32 during the last trading session, reaching $85.25. About 855,438 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 12.51% since February 19, 2017 and is uptrending. It has underperformed by 4.19% the S&P500.

Analysts expect Ormat Technologies, Inc. (NYSE:ORA) to report $0.55 EPS on February, 27.They anticipate $0.01 EPS change or 1.79% from last quarter’s $0.56 EPS. ORA’s profit would be $27.83 million giving it 29.53 P/E if the $0.55 EPS is correct. After having $0.42 EPS previously, Ormat Technologies, Inc.’s analysts see 30.95% EPS growth. The stock increased 0.39% or $0.25 during the last trading session, reaching $64.97. About 200,270 shares traded or 10.67% up from the average. Ormat Technologies, Inc. (NYSE:ORA) has risen 34.71% since February 19, 2017 and is uptrending. It has outperformed by 18.01% the S&P500.

Since September 5, 2017, it had 0 buys, and 24 selling transactions for $26.58 million activity. Another trade for 105,983 shares valued at $8.50M was sold by GORMAN KEVIN CHARLES. Another trade for 52,817 shares valued at $3.04M was made by OBrien Christopher Flint on Tuesday, September 5. $855,000 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was sold by RASTETTER WILLIAM H on Wednesday, January 24. Gano Kyle also sold $169,914 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares. Shares for $169,997 were sold by Grigoriadis Dimitri E. on Monday, February 5. 2,737 shares were sold by Lippoldt Darin, worth $227,494. The insider Bozigian Haig P. sold 26,250 shares worth $1.58 million.

Perceptive Advisors Llc decreased Nxstage Medical Inc (NASDAQ:NXTM) stake by 291,000 shares to 1.26M valued at $34.90M in 2017Q3. It also reduced Dbv Technologies S A stake by 15,346 shares and now owns 576,419 shares. Aveo Pharmaceuticals Inc (NASDAQ:AVEO) was reduced too.

Investors sentiment increased to 1.66 in 2017 Q3. Its up 0.41, from 1.25 in 2017Q2. It increased, as 22 investors sold NBIX shares while 45 reduced holdings. 32 funds opened positions while 79 raised stakes. 92.69 million shares or 0.83% more from 91.92 million shares in 2017Q2 were reported. Franklin Resource invested 0.1% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Btg Pactual Asset Mngmt Limited holds 10,118 shares or 0.2% of its portfolio. Shine Advisory Serv reported 162 shares. Legal & General Gru Public has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Grandfield & Dodd Limited Liability Com stated it has 0.05% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Raymond James And Associate owns 22,676 shares for 0% of their portfolio. Fmr Limited Liability Corp holds 13.23 million shares. Utah Retirement Sys reported 16,000 shares. Ghost Tree Ltd Liability, a New York-based fund reported 225,000 shares. Paloma Prtnrs Management, Connecticut-based fund reported 25,588 shares. Woodstock stated it has 16,578 shares or 0.19% of all its holdings. Eventide Asset Mngmt Limited Liability holds 0.43% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 125,000 shares. Metropolitan Life Ins New York holds 6,588 shares or 0% of its portfolio. Daiwa Sb Invs Ltd owns 1,954 shares for 0.02% of their portfolio. Bank & Trust Of America De stated it has 549,211 shares.

Among 13 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci had 47 analyst reports since August 18, 2015 according to SRatingsIntel. H.C. Wainwright maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Friday, August 4 with “Buy” rating. BMO Capital Markets maintained it with “Buy” rating and $84.0 target in Tuesday, October 3 report. BMO Capital Markets maintained the stock with “Buy” rating in Thursday, August 3 report. The firm has “Buy” rating given on Wednesday, February 14 by Deutsche Bank. The stock has “Buy” rating by Leerink Swann on Tuesday, October 10. BMO Capital Markets maintained the shares of NBIX in report on Friday, October 20 with “Buy” rating. Deutsche Bank initiated the stock with “Buy” rating in Thursday, November 3 report. The stock has “Buy” rating by BMO Capital Markets on Friday, July 21. The stock has “Overweight” rating by Barclays Capital on Thursday, November 2. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Outperform” rating given on Friday, January 27 by Oppenheimer.

Ormat Technologies, Inc. engages in geothermal and recovered energy power business worldwide. The company has market cap of $3.29 billion. The firm operates in two divisions, Electricity and Product. It has a 27.88 P/E ratio. The Electricity segment develops, builds, owns, and operates geothermal and recovered energy power plants; and sells electricity.

Since September 14, 2017, it had 0 buys, and 10 sales for $6.85 million activity. Shares for $144,150 were sold by Granot David. $1.45 million worth of Ormat Technologies, Inc. (NYSE:ORA) was sold by Klein Erez on Wednesday, September 27. $685,619 worth of Ormat Technologies, Inc. (NYSE:ORA) was sold by Argas Shlomi on Wednesday, September 27. Rosner Etty sold 9,983 shares worth $601,276. The insider Sullivan Bob sold $621,982. Shares for $174,096 were sold by Hatzir Shimon. Krieger Zvi sold 7,563 shares worth $467,091.

Investors sentiment decreased to 1.1 in Q3 2017. Its down 0.20, from 1.3 in 2017Q2. It turned negative, as 16 investors sold Ormat Technologies, Inc. shares while 52 reduced holdings. 18 funds opened positions while 57 raised stakes. 20.98 million shares or 1.96% more from 20.58 million shares in 2017Q2 were reported. Illinois-based Envestnet Asset Management has invested 0% in Ormat Technologies, Inc. (NYSE:ORA). Moreover, Clearbridge Invs Ltd Com has 0% invested in Ormat Technologies, Inc. (NYSE:ORA) for 66,885 shares. 3,359 were reported by Ameritas Invest Ptnrs. Northern Corporation invested in 0.01% or 495,932 shares. State Street has invested 0% in Ormat Technologies, Inc. (NYSE:ORA). New York-based Metropolitan Life Ins Co New York has invested 0.01% in Ormat Technologies, Inc. (NYSE:ORA). National Bank & Trust Of Montreal Can, a Ontario – Canada-based fund reported 11,501 shares. Nationwide Fund holds 0.02% or 89,927 shares. The New York-based Jane Street Gp Ltd has invested 0.01% in Ormat Technologies, Inc. (NYSE:ORA). Meeder Asset reported 7,084 shares. Kbc Group Nv holds 82,265 shares or 0.05% of its portfolio. Cornerstone Advisors has invested 0% in Ormat Technologies, Inc. (NYSE:ORA). Cypress Ltd Liability Co (Wy) holds 400 shares or 0.03% of its portfolio. Legal And General Gp Public Limited Com stated it has 17,006 shares or 0% of all its holdings. Glenmede Na reported 0.05% in Ormat Technologies, Inc. (NYSE:ORA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>